How about a glimpse into a place that has dedicated over a century to safeguarding public health? That place is MassBiologics. Located right here in Boston, MassBiologics stands as the only non-profit, FDA-licensed vaccine manufacturer in the United States.
MassBiologics has been tirelessly working to improve lives for over 100 years. It achieves this through applied research. It develops and produces biologic products. These include vaccines, plasma derivatives and recently, monoclonal antibodies.
Originally, MassBiologics was established in 1894. At that time it was a response to the devastating effects of diphtheria. The Commonwealth of Massachusetts Board of Health founded MassBiologics. Its initial purpose was to produce diphtheria antitoxin. This early work took place at Harvard’s Bussey Institute in Jamaica Plain.
Two decades later, MassBiologics took a significant step. It introduced diphtheria vaccine into general use in Massachusetts. Over the years, the organization expanded its efforts. It developed and manufactured biologic products for various diseases. Smallpox, typhoid, scarlet fever, tetanus and pertussis were among them.
In 1997, an administrative change occurred. The State Legislature transferred oversight of MassBiologics. It went from the Massachusetts Department of Public Health to UMass Chan Medical School. This shift fostered scientific collaborations. It enhanced technology management. It helped create partnerships. These partnerships aimed to develop products that would benefit patients.
Today, MassBiologics continues to manufacture Tetanus and Diphtheria Toxoids, Adsorbed (Td) vaccine. They distribute it nationwide. MassBiologics’ mission is clear: “Medicine for Better Lives.” They strive to discover, develop and manufacture biological medicines. These medicines aim to improve the lives of people in Massachusetts and worldwide. They also focus on educating and training a workforce. This workforce will perpetuate their public health mission.
MassBiologics envisions cultivating and disseminating knowledge. This will lead to discovering, developing and manufacturing safe and effective biologic medicines. They also focus on supporting technologies. These innovations will significantly improve public health. This includes addressing the needs of smaller patient populations. It also involves tackling emerging public health challenges. They also want to develop products for developing nations with limited resources and unique needs.
MassBiologics is an integral part of UMass Chan Medical School. It serves as a center of excellence. It educates, trains and mentors future creators of “medicines for better lives”. In the last ten years, MassBiologics has discovered four treatments that advanced into clinical trials. They also have multiple state-of-the-art facilities. They produce FDA licensed therapeutics. They also manufacture cGMP IND and pre-IND drug substances.
MassBiologics has partnered with SparingVision. They will manufacture gene therapy for ocular disease. They also collaborate with PTC Therapeutics. This collaboration involves manufacturing gene therapy for a rare pediatric condition. A preclinical study of MassBiologics’ Lyme disease prophylaxis has been published in a high impact journal. They are also developing a promising alternative treatment for diphtheria.
So, as you stand here, remember MassBiologics’ unwavering commitment. It is a commitment to public health. It is a legacy of innovation. It is a future dedicated to “Medicines for Better Lives.”